Current Opinion in Virology

Papers
(The TQCC of Current Opinion in Virology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board187
Mutational escape from cellular immunity in viral hepatitis: variations on a theme146
Colonization of peripheral ganglia by herpes simplex virus type 1 and 2116
The enigmatic roles of Anelloviridae and Redondoviridae in humans91
Hepatitis-B virus: replication cycle, targets, and antiviral approaches91
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?77
Transmission patterns of hepatitis E virus75
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-1969
Inhaled aerosol viral-vectored vaccines against tuberculosis68
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy68
Editorial Board63
Editorial overview: Viral pathogenesis56
Human placental models for studying viral infections52
Viral–host interactions during splicing and nuclear export of influenza virus mRNAs50
Structural basis for neutralization of enterovirus49
Virus–host protein interactions as footprints of human cytomegalovirus replication47
Editorial overview: Mechanisms in the molecular interactions of plants with viruses and viroids46
Editorial Board44
Recent progress in development of monoclonal antibodies against human cytomegalovirus43
Time to ‘Mind the Gap’ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-242
The two faces of oligoadenylate synthetase-like: effective antiviral protein and negative regulator of innate immunity40
New preventive strategies for respiratory syncytial virus infection in children40
Hepatitis C virus envelope protein dynamics and the link to hypervariable region 139
Emerging technologies in the study of the virome39
Paramyxoviruses from bats: changes in receptor specificity and their role in host adaptation37
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection35
Shopping for phages? Unpacking design rules for therapeutic phage cocktails35
The journey of herpesvirus capsids and genomes to the host cell nucleus35
A complex immune communication between eicosanoids and pulmonary macrophages32
The enigma of picobirnaviruses: viruses of animals, fungi, or bacteria?32
Platelets in the pathogenesis of flavivirus disease32
A review of broadly protective monoclonal antibodies to treat Ebola virus disease31
Mitigation of evolved bacterial resistance to phage therapy30
Perspective on taxonomic classification of uncultivated viruses29
Epigenetic control of the Epstein-Barr lifecycle28
Engineering therapeutic phages for enhanced antibacterial efficacy28
Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome: challenges and opportunities27
When good turns bad: how viruses exploit innate immunity factors27
Editorial Board27
Asymmetry in icosahedral viruses27
Retasking of canonical antiviral factors into proviral effectors26
Does arbovirus emergence in humans require adaptation to domestic mosquitoes?26
Hemagglutinin stability as a key determinant of influenza A virus transmission via air26
Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity26
Tissue-resident memory T cells in protective immunity to influenza virus26
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity25
Role of the viral polymerase during adaptation of influenza A viruses to new hosts24
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets24
Immune responses to human respiratory coronaviruses infection in mouse models24
Modeling zoonotic and vector-borne viruses24
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy24
Mechanisms of HCV resistance to broadly neutralizing antibodies24
The virome of vector mosquitoes23
Oncogenic Animal Herpesviruses23
MicroRNA-mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications23
Diagnosis and monitoring of virus-associated cancer using cell-free DNA22
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases22
Deimmunization of flagellin adjuvant for clinical application22
Bat virome research: the past, the present and the future21
Advances in human monoclonal antibody therapy for HBV infection21
Antigenic evolution of SARS coronavirus 221
The impact of high-resolution structural data on stemming the COVID-19 pandemic21
0.046951055526733